Elevance Health Inc (ELV)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $92.84B
Last updated: Nov 17, 2026 at 11:05 AM ET
Elevance Health Inc (ELV) Stock Forecast
Analysts expect Elevance Health (ELV) to earn $29.14 per share in the fiscal year ending Dec 31, 2026, on revenue of $198.85B. Of 22 analysts, 15 rate the stock Buy or Strong Buy, 7 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 20 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 22 ratings average 2.18, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 68% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 13.6% |
| Buy | 12 | 54.5% |
| Hold | 7 | 31.8% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 22
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 3.9% and revenue estimates rise 2.5%.
- Fiscal year ending Dec 31, 2026
- $29.14
- EPS consensus, revenue $198.85B
- Fiscal year ending Dec 31, 2027
- $30.29
- EPS consensus, revenue $203.75B
- Next report
- Jan 26, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $29.14 | $28.65 to $30.28 | 21 | $198.85B | $196.78B to $200.05B | 12 |
| Dec 31, 2027 | $30.29 | $29.95 to $31.75 | 21 | $203.75B | $197.12B to $209.77B | 12 |
Quarterly Estimates
The EPS consensus rises from $2.08 for the quarter ending Dec 31, 2026 to $12.32 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.08 | $1.61 to $3.38 | 23 | $49.74B | $46.08B to $52.81B | 19 |
| Mar 31, 2027 | $12.32 | $8.69 to $13.23 | 14 | $50.06B | $49.26B to $51.06B | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 47 upward and 5 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 20 | 0 |
| Fiscal year ending Dec 31, 2027 | 19 | 1 |
| Quarter ending Mar 31, 2027 | 8 | 4 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 7.3% from $27.16.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $29.14 | $29.14 | $27.20 | $27.16 | $27.16 | +7.3% |
| Fiscal year ending Dec 31, 2027 | $30.29 | $30.29 | $29.58 | $29.61 | $29.63 | +2.2% |
| Quarter ending Mar 31, 2027 | $12.32 | $12.14 | $12.12 | $12.03 | $12.03 | +2.4% |
Frequently Asked Questions About ELV
What is the ELV stock forecast?
Consensus analyst estimates put Elevance Health's EPS at $29.14 for the fiscal year ending Dec 31, 2026, on revenue of $198.85B. The consensus rating from 22 analysts is Buy.
How do analysts rate ELV stock?
Of 22 analysts covering Elevance Health, 3 rate it Strong Buy, 12 Buy, 7 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ELV next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $29.14, with estimates from $28.65 to $30.28 from 21 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $30.29, with estimates from $29.95 to $31.75 from 21 analysts.
What revenue do analysts expect from Elevance Health next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $198.85B, with estimates from $196.78B to $200.05B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $203.75B, with estimates from $197.12B to $209.77B.
How many analysts cover ELV?
22 analysts rate Elevance Health stock, and 21 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ELV pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts